drug-related adverse reaction leading to caspofungin discontinuation was The printed package leaflet of the medicinal product must state the name and. CANCIDAS® is a sterile, lyophilised product for intravenous infusion that contains a Interpretive standards (or breakpoints) for caspofungin against Candida. CANCIDAS* is a sterile, lyophilized product for intravenous (IV) infusion that CANCIDAS is the first of a new class of antifungal drugs (glucan synthesis.

Author: Dale Gagor
Country: Burkina Faso
Language: English (Spanish)
Genre: Love
Published (Last): 25 April 2014
Pages: 180
PDF File Size: 13.85 Mb
ePub File Size: 12.55 Mb
ISBN: 161-4-17465-293-4
Downloads: 3676
Price: Free* [*Free Regsitration Required]
Uploader: Mikazragore

Moderate Use dichlorphenamide and caspofungin together with caution. Infants 1 to 2 months. These mutations are associated with higher MICs and breakthrough infection.

Because of its unique mechanism of action, cross-resistance with amphotericin B and the azoles is not expected. Disclaimer The authors make no canicdas of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgment. Monitor potentially exposed infants for gastrointestinal adverse events and signs of histamine release.

If the mg dose is well tolerated but does not provide an adequate clinical response, the daily dose can be increased to 70 mg.

Caspofungin vials are single use only; discard any unused reconstituted solution. Distribution, the primary mechanism influencing plasma clearance, follows a three-compartment model.

Esophageal Candidiasis The dose should be 50 mg daily. In addition, some Candida sp. For the treatment of Candida pneumonia and pleural space infections. Dosage adjustment information is only available cahcidas adults.

For infection involving a prosthetic device, device removal in addition to antifungal therapy is recommended. Administering inducers of hepatic cytochrome P, such as efavirenz, concurrently with caspofungin may reduce the plasma concentrations of caspofungin. Reference s National Institutes of Health, U. The reductions may be clinically significant. If this occurs, discontinue Caspofungin and administer appropriate treatment.


Caspofungin has shown activity against Candida species and in regions of active cell growth of the hyphae of Aspergillus fumigatus. Plasma concentrations of caspofungin decline in a polyphasic manner following camcidas 1-hour intravenous IV infusions. Reconstituted caspofungin in the vial may be stored at 25 degrees C or less 77 degrees F or less for 1 hour prior to dilution. Empirical therapy should be continued until resolution of neutropenia.

PDR Search

A local search option of this inert can be found here. Duration of therapy is dependent on clinical response. National Institutes of Health, U. However, site of infection, local susceptibility patterns, and specific microbial susceptibility should be assessed before choosing an alternative agent. For empirical therapy for presumed fungal infection in patients with febrile neutropenia. Duration of treatment is based on clinical response. Your email has been sent.

In general, the safety profile of caspofungin in pediatric patients is comparable to that of adult patients. Patients who remain persistently neutropenic may warrant a longer course of therapy pending resolution of the neutropenia.

Monitor patients who develop abnormal liver enzyme concentrations; a risk versus benefit decision for therapy continuation is recommended.

Coadministration of certain drugs may need to be avoided or dosage adjustments may be necessary; review drug interactions. Remove peritoneal dialysis catheter.

Caspofungin Acetate for Injection Now Available from Fresenius Kabi – Fresenius Kabi USA

Patients with hepatic disease, or those with cholestasis, hepatitis or jaundice may require a dose adjustment of caspofungin. For the treatment of intraabdominal aspergillosis in patients who are refractory to or intolerant of other antifungal therapies. It is not known how caspofungin drug clearance is induced. Increased dosage of tacrolimus may be required. The mechanism of this interaction has not been identified but has been reported with tacrolimus; monitor sirolimus blood concentrations and adjust sirolimus dosage as required.


Treatment for at least 14 days and for at least 7 days after neutropenia and symptoms resolve is recommended for patients found to have a fungal infection.

Your Name Your name is required. Cyclosporine concentrations are not altered by coadministration with caspofungin. Isolated cases of hepatic dysfunction, hepatitis, or hepatic failure have been reported. For the treatment of Aspergillus pneumonia and pleural space infections in patients who are refractory to or intolerant of other antifungal therapies. IV echinocandin antifungal Used for aspergillosis, candidemia, esophageal candidiasis, and empiric treatment in febrile neutropenia Fever and infusion-related reactions common.

Caspofungin inhibits the synthesis of a major fungal cell wall component, beta 1,3 -D-glucan. For the treatment of intraabdominal infections i. Major If rifampin and caspofungin are administered together in adult patients, the manufacturer recommends increasing the dose of caspofungin to 70 mg daily. Patients found to have a fungal infection should be treated for a minimum of inwert days; treatment should continue for at least 7 days after both neutropenia and clinical symptoms are resolved.